Development of natural polymers-based inhaled microspheres for tuberculosis
DOI:
https://doi.org/10.46542/pe.2024.243.123128Keywords:
Anti-tuberculosis, Inhalation, Microsphere, Natural polymer, TuberculosisAbstract
Background: Tuberculosis (TB) is a contagious disease caused by Mycobacterium tuberculosis (Mtb) that mainly affects the lungs (pulmonary TB). Treatment involves a 6-month regimen of four first-line anti-TB drugs: isoniazid (INH), rifampicin (RIF), ethambutol (ETH), and pyrazinamide (PZA). However, the effectiveness of this regimen is limited due to the protection of Mtb bacteria in lung lesions. An alternative approach involves delivering the drugs directly to the lungs through inhalation using innovative methods of microspheres, which can greatly enhance treatment efficacy.
Objective: This review focuses on inhaled microspheres that use natural polymers for anti-tubercular drugs.
Method: A comprehensive literature survey was pulled from databases (PubMed, Scopus, Google Scholar, and ScienceDirect) from 2012 to 2022.
Result: The characterisation studies, formulation technique, and efficacy using in vitro and in vivo studies of anti-tuberculosis drugs inhaled microspheres.
Conclusion: Microspheres have substantial potential as an inhaled drug delivery system and are likely to have significant clinical contributions in the future.
References
Ahmad, I., Ungphaiboon, S., & Srichana, T. (2014). The development of dimple-shaped chitosan carrier for ethambutol dihydrochloride dry powder inhaler. Drug Development and Industrial Pharmacy, 41(5), 791–800. https://doi.org/10.3109/03639045.2014.903493
Bangar, B., Shinde, N., Deshmukh, S., Kale, B. (2014). Natural polymers in drug delivery development. Research Journal of Pharmaceutical Dosage Forms and Technology, 6(1), 54–57.
Bagcchi, S. 2023. WHO’s global tuberculosis report 2022. The Lancet Microbe, 4(1), e20. https://doi.org/10.1016/s2666-5247(22)00359-7
Choudhury, A., Deka, D., Sonowal, K., & Laskar, R. E. (2019). Microsphere: A promising approach for drug delivery. Journal of Applied Pharmaceutical Research, 7(2), 1–6. https://doi.org/10.18231/j.joapr.2019.001
Garg, T., Goyal, A. K., Rath, G., & Murthy, R. S. R. (2015). Spray-dried particles as pulmonary delivery system of anti-tubercular drugs: design, optimization, in vitro and in vivo evaluation. Pharmaceutical Development and Technology, 21(8), 951–960. https://doi.org/10.3109/10837450.2015.1081613
Grenha, A., Alves, A. D., Guerreiro, F., Pinho, J. O., Simões, S., Almeida, A. J., & Gaspar, M. M. (2020). Inhalable locust bean gum microparticles co-associating isoniazid and rifabutin: Therapeutic assessment in a murine model of tuberculosis infection. European Journal of Pharmaceutics and Biopharmaceutics, 147, 38–44. https://doi.org/10.1016/j.ejpb.2019.11.009
Hariyadi, D. M. (2018). In vivo neuroprotective activity of erythropoietin-alginate microspheres at different polymer concentrations. Asian Journal of Pharmaceutics, 12(4), 255–260. https://doi.org/10.22377/ajp.v12i04.2833
Hariyadi, D. M., Purwanti, T., Maulydia, D., Estherline, C. A., Hendradi, E., & Rahmadi, M. (2021). Performance and drug deposition of kappa-carrageenan microspheres encapsulating ciprofloxacin HCl: Effect of polymer concentration. Journal of Advanced Pharmaceutical Technology & Research, 12(3), 242–249. https://doi.org/10.4103/japtr.japtr_197_21
Kaur, G., Narang, R. K., Rath, G., & Goyal, A. K. (2012). Advances in pulmonary delivery of nanoparticles. Artificial Cells, Blood Substitutes, and Biotechnology, 40(1–2), 75–96. https://doi.org/10.3109/10731199.2011.592494
Kaur, R., Garg, T., Malik, B., Gupta, U. D., Gupta, P., Rath, G., & Goyal, A. K. (2014). Development and characterization of spray-dried porous nano aggregates for pulmonary delivery of anti-tubercular drugs. Drug Delivery, 23(3), 872–877. https://doi.org/10.3109/10717544.2014.920428
Khadka, P., Dummer, J., Hill, P. C., & Das, S. C. (2018). Considerations in preparing for clinical studies of inhaled rifampicin to enhance tuberculosis treatment. International Journal of Pharmaceutics, 548(1), 244–254. https://doi.org/10.1016/j.ijpharm.2018.07.011
Khadka, P., Dummer, J., Hill, P. C., Katare, R., & Das, S. C. (2022). A review of formulations and preclinical studies of inhaled rifampicin for its clinical translation. Drug Delivery and Translational Research, 13(5), 1246–1271. https://doi.org/10.1007/s13346-022-01238-y
Lengyel, M., Kállai-Szabó, N., Antal, V., Laki, A. J., & Antal, I. (2019). Microparticles, microspheres, and microcapsules for advanced drug delivery. Scientia Pharmaceutica, 87(3), 20. https://doi.org/10.3390/scipharm87030020
Manca, M. L., Cassano, R., Valenti, D., Trombino, S., Ferrarelli, T., Picci, N., Fadda, A. M., & Manconi, M. (2013). Isoniazid-gelatin conjugate microparticles containing rifampicin for the treatment of tuberculosis. Journal of Pharmacy and Pharmacology, 65(9), 1302–1311. https://doi.org/10.1111/jphp.12094
Maretti, E., Rossi, T., Bondi, M., Croce, M. A., Hanuskova, M., Leo, E. G., Sacchetti, F., & Iannuccelli, V. (2014). Inhaled solid lipid microparticles to target alveolar macrophages for tuberculosis. International Journal of Pharmaceutics, 462(1–2), 74–82. https://doi.org/10.1016/j.ijpharm.2013.12.034
Miranda, M. S., Rodrigues, M. T., Domingues, R. M. A., Torrado, E., Reis, R. L., Pedrosa, J., & Gomes, M. E. (2018). Exploring inhalable polymeric dry powders for anti-tuberculosis drug delivery. Materials Science and Engineering: C, 93, 1090–1103. https://doi.org/10.1016/j.msec.2018.09.004
Omar, S. M., Maziad, N. A., & El-Tantawy, N. M. (2019). Pulmonary delivery of isoniazid in nanogel-loaded chitosan hybrid microparticles for inhalation. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 32(2), 78–87. https://doi.org/10.1089/jamp.2018.1460
Patil, J. S., Devi, K., Devi, K., & Suresh, S. (2015). Formulation and evaluation of novel spray-dried alginate microspheres as pulmonary delivery systems of rifampicin in rats. Indian Journal of Pharmaceutical Education and Research, 49(4), 320–328. https://doi.org/10.5530/ijper.49.4.9
Rodrigues, S., Cunha, L., Rico, J., Da Costa, A. M. R., Almeida, A. J., Faleiro, M. L., Buttini, F., & Grenha, A. (2020). Carrageenan from red algae: an application in the development of inhalable tuberculosis therapy targeting the macrophages. Drug Delivery and Translational Research, 10(6), 1675–1687. https://doi.org/10.1007/s13346-020-00799-0
Rosita, N., Kalalo, T., Miatmoko, A., Pathak, Y., & Hariyadi, D. M. (2022). Microspheres for inhalation delivery (Characteristics and in vitro release). International Journal of Medical Reviews and Case Reports, 6(2), 24–31. https://doi.org/10.5455/ijmrcr.microspheresforinhalationdelivery
Sibum, I., Hagedoorn, P., Frijlink, H. W., & Grasmeijer, F. (2019). Characterization and formulation of isoniazid for high-dose dry powder inhalation. Pharmaceutics, 11(5), 233. https://doi.org/10.3390/pharmaceutics11050233
